A cluster randomised controlled trial and process evaluation of a training programme for mental health professionals to enhance user involvement in care planning in service users with severe mental health issues (EQUIP): study protocol for a randomised controlled trial by Bower, Peter et al.
TRIALS
Bower et al. Trials  (2015) 16:348 
DOI 10.1186/s13063-015-0896-6STUDY PROTOCOL Open AccessA cluster randomised controlled trial and
process evaluation of a training programme for
mental health professionals to enhance user
involvement in care planning in service users
with severe mental health issues (EQUIP): study
protocol for a randomised controlled trial
Peter Bower1*, Chris Roberts3, Neil O’Leary3, Patrick Callaghan4, Penny Bee2, Claire Fraser2, Chris Gibbons2,
Nicola Olleveant2, Anne Rogers5, Linda Davies6, Richard Drake2,7, Caroline Sanders1, Oonagh Meade4,
Andrew Grundy4, Lauren Walker2, Lindsey Cree2, Kathryn Berzins2, Helen Brooks2, Susan Beatty2, Patrick Cahoon7,
Anita Rolfe7 and Karina Lovell2Abstract
Background: Involving service users in planning their care is at the centre of policy initiatives to improve mental
health care quality in England. Whilst users value care planning and want to be more involved in their own care,
there is substantial empirical evidence that the majority of users are not fully involved in the care planning process.
Our aim is to evaluate the effectiveness and cost-effectiveness of training for mental health professionals in
improving user involvement with the care planning processes.
Methods/Design: This is a cluster randomised controlled trial of community mental health teams in NHS Trusts in
England allocated either to a training intervention to improve user and carer involvement in care planning or
control (no training and care planning as usual).
We will evaluate the effectiveness of the training intervention using a mixed design, including a ‘cluster cohort’
sample, a ‘cluster cross-sectional’ sample and process evaluation. Service users will be recruited from the caseloads
of care co-ordinators.
The primary outcome will be change in self-reported involvement in care planning as measured by the validated
Health Care Climate Questionnaire. Secondary outcomes include involvement in care planning, satisfaction with
services, medication side-effects, recovery and hope, mental health symptoms, alliance/engagement, well-being and
quality of life. Cost- effectiveness will also be measured. A process evaluation informed by implementation theory
will be undertaken to assess the extent to which the training was implemented and to gauge sustainability beyond
the time-frame of the trial.
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Discussion: It is hoped that the trial will generate data to inform mental health care policy and practice on care
planning.
Trial Registration Number: ISRCTN16488358 (14 May 2014)
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Involving service users in their own care and allowing
choice is at the centre of policy initiatives aimed at im-
proving quality of care and enhancing recovery. This
principle is enshrined and prioritised in health care [1, 2],
particularly mental health care policy and guidelines [3, 4].
Current guidance states that the outcome of any assess-
ment will be a care plan developed with the service user,
the professional/member of the care team and other ap-
propriate parties, such as families and carers [5, 6]. Mental
health nurses, psychiatrists and allied health and social
care workers provide the majority of care for service users
regardless of setting. They have a pivotal role in the devel-
opment of care planning, particularly as care co-
ordinators under the Care Programme Approach (CPA)
[5, 6]. Despite the consensus among policy-makers, pro-
fessionals, service users and carers about the importance
of involvement there is substantial empirical evidence that
the majority of users and carers are marginalised in the
care planning process. This lack of involvement occurs in
both in-patient and community settings [7, 8] and there is
evidence that current models of involving users and carers
in their care are less effective than first envisaged.
One of the key findings of the Care Quality Commis-
sion’s national survey, which included 7500 users of men-
tal health services, was that service users were often not
involved in their care as much as they wanted to be, with
only 34 % agreeing that they were ‘definitely’ involved as
much as they wanted to be in decisions about their care
and treatment [7, 8]. A significant number of studies of
user and carer experience echo the need and desire to be
involved in their care [9], but despite this evidence there
has been little change in practice. There is also evidence
that carers feel excluded, unsupported and distanced by
mental health services and want to be more involved in
the care planning process [10–13]. A systematic review of
user and carer views and expectations of mental health
nurses, including 132 papers over a 20-year period [14],
found that users and carers expressed a need for openness
and adequate information, more choice and increased in-
volvement in the assessment and planning of their care.
Perhaps most importantly it found that the literature re-
mains strikingly consistent over time, indicating a sus-
tained lack of impact on practice.
This research aims to develop a standardised training
intervention (EQUIP training) to improve user and carerinvolvement with the care planning process, and to test
the effectiveness and cost-effectiveness of this package.
The study is a pragmatic effectiveness and cost-
effectiveness trial and, thus, the optimal comparator is
a no training control representing usual practice.
If proven effective and cost-effective, it will provide a
model for wider implementation to improve the quality
of mental health care across community mental health
services.
Objectives
To conduct a cluster randomised controlled trial (RCT)
of effectiveness and cost-effectiveness of the EQUIP
training for improving involvement of service users and
carers compared with controls in UK National Health
Service (NHS) community mental health services.
Methods/Design
As the trial involves a health professional training inter-
vention, a cluster randomised design is required to avoid
contamination. A mixed design, including a ‘cluster co-
hort’ design, a ‘cluster cross-sectional’ design and process
evaluation will be adopted (see Fig. 1 for an outline of the
trial design, and Fig. 2 for the Consolidated Standards of
Reporting Trials (CONSORT) flow diagram). Adoption of
the combined design provides protection against problems
in either of the individual approaches.
In the ‘cluster cohort’ design, service users cared for
by each Community Mental Health Team (CMHT) will
be recruited, and a detailed face-to-face assessment will
be conducted at baseline. Carers will be recruited from
consenting service users. Each CMHT will then be ran-
domised to either intervention (training in care plan-
ning) or control (usual care planning). The CMHTs
randomised to intervention will then receive the EQUIP
training. Six-month follow-up face-to-face assessments
will then be conducted with the same service users and
carers (intervention and control groups) 6 months after
the baseline assessment.
For the cluster cohort, service users need to participate
in two face-to-face assessments, which may be burden-
some to service users. This means the cluster cohort
may be vulnerable to recruitment difficulties (i.e., only a
small number of eligible service users take part) and at-
trition (i.e., service users do not attend for follow-up),
reducing both sample size and external validity.
Fig. 1 EQUIP trial design
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sectional’ element to help ameliorate problems of re-
cruitment and attrition within the cluster cohort. Six
months after randomisation, a smaller number of ques-
tionnaires (see Table 1) will be posted to all service users
who are not part of the ‘cluster cohort’ but who are
under the care of all participating teams.
Service users in the cross-sectional sample only have
to agree to assessment once, and the assessment is de-
signed to be less burdensome as it includes fewer mea-
sures. This means that a higher proportion of service
users may agree to take part in the study, potentially giv-
ing a larger sample size.However, the ‘cluster cohort’ design allows adjustment
for a wider range of baseline characteristics at an indi-
vidual level because of the greater range of measures
included, giving potentially greater statistical power
compared to analysis of the ‘cluster cross-sectional’ data
[15]. Comparative analyses of data from the two designs
will allow the possibility of pooling results from the two
designs to be investigated.
A potential threat to the validity of a cluster rando-
mised trial is recruitment bias, where professionals allo-
cated to different trial arms recruit differently depending
on their allocation, leading to selection bias and baseline
incomparability [16]. Whilst it is preferable to recruit
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) diagram
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means that clusters will need advanced notice of their
training date, which will require us to inform them of
their allocation. Therefore, initial patient selection in the
EQUIP trial is not by those being trained in the trial, but
will use existing registers of service users. This will be
undertaken by NIHR Clinical Research Network Clinical
Studies Officers (CSO) and Trust staff. This will limit
the opportunity for biased recruitment. Carers will be
recruited by providing service users with a recruitment
pack to give to their carer (if a carer is identified and
wishes to consider taking part).
A longitudinal process evaluation of the training
programme is being undertaken which incorporates mul-
tiple interviews over time, observations and diary methods
of data collection. This will run alongside the trial and is
being conducted because successful implementation of
user and carer-led care planning implicates a range of fac-
tors including the integrity of the intervention and theacceptability of the intervention to both clinicians and ser-
vice users [17].
Study setting and inclusion criteria
Community Mental Health Teams (CMHTs)
The study is being conducted in NHS Trusts in the UK.
All CMHTs within the participating NHS Trusts will
be eligible for inclusion. Service users aged 18 and over
with a severe mental illness (e.g., psychosis, bipolar dis-
order, schizophrenia) under the care of participating
CMHTs will be eligible for inclusion. We will seek con-
sent from service users to access health records to col-
lect data on diagnosis, service use and treatment history.
Intervention design – User/carer-led training package to
inform care planning
All consenting CMHTs allocated to the intervention arm
will receive the EQUIP training intervention developed
in our earlier work. The EQUIP training intervention
Table 1 Outcome measures used with the 3 sample groups at baseline and 6-month follow-up
Sample Baseline Six months
Service user cohort (face-to-face collection) Demographic data
Primary outcome: Primary outcome:
HCCQ-10 HCCQ-10
Secondary outcomes: Secondary outcomes:
VSSS-EU-54 VSSS-EU-54
GASS GASS
WEMWBS WEMWBS
DREEM DREEM
HADS HADS
CALPAS-12 CALPAS-12
WHOQOL-BREF WHOQOL-BREF
PROM PROM
Economic outcome: Economic outcome:
EQ-5D-5L EQ-5D-5L
Service use questionnaire Service use questionnaire
Carer cohort (postal collection) Demographic data
Secondary outcomes: Secondary outcomes:
PROM PROM
CUES-C CUES-C
WHOQOL-BREF WHOQOL-BREF
Economic outcome: Economic outcome:
EQ-5D-5L EQ-5D-5L
Cross-sectional sample: service users (postal collection) Demographic data
Primary outcome:
HCCQ-10
Secondary outcome:
PROM (14-item SF version)
Economic outcome:
EQ-5D-5L
Service use questionnaire
CALPAS-12 California Psychotherapy Alliance Scales, CUES-C Carers’ and Users’ Expectations of Services – carer version, DREEM Developing Recovery Enhancing
Environments Measure, EQ-5D-5L EuroQol-5D-5L, GASS Glasgow Antipsychotic Side-effect Scale, HADS Hospital Anxiety and Depression Scale, HCCQ-10 Health Care
Climate Questionnaire, PROM Patient Reported Outcome Measure, WHOQOL-BREF World Health Organisation Quality of Life., VSSS-EU-54 Verona Service Satisfaction
Scale, WEMWBS World Health Organisation Quality of Life
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tional self-directed learning package and 6 hours super-
vision per team in the 6 months following the training.
In recruitment of teams, we ask that at least 80 % of staff
designated as ‘care co-ordinators’ (i.e., those with a case-
load) commit to attend the training. We will document
attendance at training by all professionals.Comparator – Usual care
This will consist of ‘usual practice’ in care planning, with-
out access to the specialist training described above. We
will have considerable detail about what ‘usual practice’consists of and how it varies from unit to unit from the
embedded process evaluation.
Intervention components
We describe the intervention according to the Template
for Intervention Description and Replication (TIDieR)
guidelines [18]:
a) Why: our aim was to co-develop, co-produce and
co-deliver (with service users/carers) a best evidence,
acceptable and feasible training programme for men-
tal health professionals to enhance user and carer in-
volvement in care planning. Two reviews were
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in press) which examined how user-involved care
planning is operationalised within mental health ser-
vices and to establish where, how and why chal-
lenges to user involvement occur; and a scoping
review of training reviews and interventions that
change clinician behaviour. In addition, focus groups
and individual interviews with service users, carers
and health professionals were conducted to ascertain
training content and delivery requirements and to
determine the priorities and components of ad-
equate user and carer involvement in care planning.
The evidence from the reviews and qualitative data
was synthesised to develop and design the training.
b) What: a range of training materials have been
developed for the training including PowerPoint
slides, case scenarios, audio-recordings from health
professionals, service users and carers and a trainer’s
manual.
c) Who: the synthesis identified that the training
should be multi-disciplinary, including all health
professionals and psychiatrists. Team training was
seen as optimal and, as far as possible, teams will
be trained together. The training will be delivered
by 2 of the co-applicants (both academics with
teaching experience) and 3/4 service users and
carers who have attended a 4-day ‘train the
trainers’ course.
d) How: the synthesis indicated that training should
include a range of formats: face-to-face, self-directed
learning and follow-up supervision. The consensus
exercise indicated a minimum of 15 hours and max-
imum of 30. The course will run for 2 days (12
hours) plus 6 hours follow-up supervision and 8
hours self-directed learning (optional). Hence, each
health professional will receive 18 hours of facilitated
training and an additional optional 8 hours self-
directed learning.
e) Where: consensus was reached that the training
venue should be outside the clinical area,
geographically convenient, provide good catering
and in a venue with appropriate training resources.
f ) When and how: the training will be delivered to
each cluster randomised to the training intervention
over 2 days. In recruiting teams, we ask that 80 % of
the care co-ordinators within each team attend the
training. The training will be delivered within 6
weeks of service users being recruited into the trial.
g) Tailoring: the intervention has been tailored for
health professionals.
h) Modifications: only minor modifications will be
made in light of feedback during the trial. If the trial
is successful and we implement the training across
other NHS Trusts, modifications will be made inlight of feedback collected from the process
evaluation.
i) How well: fidelity of the training has been ensured
by the careful development and synthesis work
described earlier, the ‘train the trainers’ course, the
development of a detailed manual and the delivery
of training by the same groups of trainers.Outcome assessment
Primary outcome
The Health Care Climate Questionnaire (HCCQ-10)
[19] is the primary outcome measure for the service
users in the trial.
The HCCQ-10 was developed to assess patient experi-
ence of health care and the degree to which their care
offers support for autonomy. The scale has ten items,
which are scored on a seven-point scale ranging from
‘strongly disagree’ to ‘strongly agree’. An overall score is
calculated as the mean of the items (expressed out of
100), where a higher score indicates greater support for
autonomy.Secondary outcomes
Secondary outcome measures were determined using ex-
perts and a consensus discussion exercise with the ser-
vice user/carer advisory group. Key domains to measure
were recommended by the service user/carer advisory
group in our earlier Programme Development Grant (RP-
DG-1209-10020). The domains identified were: quality of
life; alliance/engagement; service satisfaction; well-being;
mental health symptoms; hope and recovery; and medica-
tion side-effects. Six of these domains have one question-
naire selected for completion, whilst the domain
‘satisfaction’ has separate questionnaires for both service
users and carers.
A new measure of user involvement in care planning,
the Patient Reported Outcome Measure (PROM) was
developed in consultation with our user and carer advis-
ory group. The need for this measure was determined
during the development of this grant as existing mea-
sures of user involvement were not deemed adequate by
the advisory group as they failed to sufficiently incorpor-
ate the views of users. The newly developed PROM will
be included as a secondary outcome to measure user
and carer involvement in care planning. The new meas-
ure has been validated using the Rasch model and has
displayed excellent psychometric and scaling properties
[20]. The 61-item scale (and 14-item short form version)
is suitable for both service users and carers. Items are
scored on a five-point Likert scale from ‘Completely dis-
agree’ to ‘Completely agree’. Higher scores reflect greater
service user and carer involvement with care planning.
Data from this study will provide further evidence of the
Bower et al. Trials  (2015) 16:348 Page 7 of 13acceptability, validity and sensitivity to change of this
measure for this population.
Satisfaction (service users)
Verona Service Satisfaction Scale (VSSS-EU-54) [21, 22],
is a validated, multi-dimensional, self-administered scale
for measuring service users’ satisfaction with mental
health services. There are seven dimensions: overall sat-
isfaction, professional skill and behaviour, access, effi-
cacy, types of intervention and relatives’ involvement.
Participants are asked to express their overall feeling
about their experience of the mental health service they
have been attending in the last year. Satisfaction ratings
are on a five-point Likert scale, with higher scores repre-
senting greater satisfaction. Global and subscale scores
can be obtained. Reliability testing has shown that the
VSSS-EU-54 has good internal consistency and stability.
Satisfaction (carers)
Carers and Users’ Expectations of Services - carer ver-
sion (CUES-C) [23] will be used to measure carers’
views of services. There are three parts to the question-
naire; part A measures the impact of caring, part B mea-
sures the quality of support provided by carers and part
C is a free text response for advice and help. The self-
rating scales consist of 13 items each in parts A and B,
totalling 26 questions. All questions are answered using
a three-point scale. Scores for each part range from 0 to
26, with higher scores representing more dissatisfaction
and the need for more support. The scale has been
found to be suitable to use to assess carers’ experiences.
Medication side-effects
The Glasgow Antipsychotic Side-effect Scale (GASS)
[24] is a self-rating scale to detect the side-effects of
antipsychotic medication. The scale consists of 22 ques-
tions and scores range from 0 to 66. Higher scores re-
flect more frequent experience of side-effects, with
total scores providing three categories of severity (ab-
sent/mild side-effects, moderate side-effects and severe
side-effects).
Well-being
The Warwick-Edinburgh Mental Well-being Scale
(WEMWBS) [25] is a short, psychometrically robust scale,
which is easy to complete. It has 14 items scored on a 5-
point Likert scale ranging from ‘none of the time’ to ‘all of
the time’ based on experience over the past 2 weeks.
Scores range from 14–70 and a higher score indicates a
higher level of mental well-being.
Recovery and hope
Developing Recovery Enhancing Environments Measure
(DREEM) [26] is a self-report measure used to assessmental health recovery of people who receive mental
health services. It is a 166-item questionnaire which is
organised into 24 subscales (such as ‘stage of recovery’
and ‘elements of recovery’), including a final section con-
sisting of open-ended questions. Responses are scored
on a five-point Likert scale ranging from ‘strongly agree’
to ‘strongly disagree’, with low scores representing more
positive experience.
Symptoms
Hospital Anxiety and Depression Scale (HADS) [27] is
a 14-item scale using a 4-point Likert scale. Items are
added to give two scores, one for anxiety and one for
depression, with higher scores representing more severe
symptoms. Scores range from 0 to 21 for both anxiety
and depression. This is a well-used and validated
measure.
Alliance/engagement
California Psychotherapy Alliance Scale (CALPAS) [28]
is a 12-item, self-report questionnaire, which provides a
total score. It has four subscales: ‘service user capacity to
work purposefully in therapy’, ‘the affective bond with
the therapist’, ‘therapist’s empathic understanding’ and
‘involvement and the agreement between the patient and
therapist on the goals and tasks of treatment’. Each item
is rated on a 6-point Likert scale, with scores ranging
from 12 to 84, with higher scores representing better al-
liance. It has good reliability and validity.
Quality of life
World Health Organisation Quality of Life (WHOQOL-
BREF) [29] is a 26-item questionnaire consisting of 4 do-
mains (physical, psychological, social relationships and
environment). Each question uses a 5-point Likert scale,
ranging from a score of 1 to 5, with higher scores repre-
senting more positive ratings. Total scores are computed
within each domain. It has been shown to demonstrate
good reliability and validity.
Economic outcome
Health Status
The EQ-5D-5L [30] will be used to assess health status
and to estimate Quality-Adjusted Life Years (QALYs),
using published EQ-5D utility weights for the UK.
QALYs will be the primary measure of health benefit for
the economic analysis. The EQ-5D-5L, has two parts;
part 1, a 5-item questionnaire consisting of 5 dimensions
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression). Each dimension has five levels, ran-
ging from no problems to severe problems. The five di-
mensions can be combined to describe the respondents’
health state. Part 2 is a visual analogue scale (VAS)
which records respondents’ self-rated health on a vertical
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health state’ and ‘worst imaginable health state’.
Service use questionnaire
A Service Use Questionnaire will be used at baseline and
follow-up to identify the range of services used by each
trial participant and how much they have used each ser-
vice. The measure will be used to estimate the costs of
health and social care service use.
Use of outcome measures and methods of data collection
Use of outcome measures with the three sample groups
(service user cohort, carer cohort, cross-sectional co-
hort) is further detailed in Table 1.
Service user cohort sample
Demographic data, primary, secondary and economic
outcome measures will be collected via a face-to-face as-
sessment. As the ‘cluster cohort’ assessment is more bur-
densome, service users will receive a £10 voucher for
their time after completion of the follow-up interview at
6 months.
Carer cohort sample
Demographic data, primary, secondary and economic
outcome measures will be collected via a postal method.
Carers will receive a £5 voucher following receipt of the
follow-up questionnaires at the 6-month time point.
Cross-sectional sample (service users)
Demographic data, primary, secondary and economic
outcome measures will be collected via a postal method
at the 6-month time point. There will be no collection
of carer information in the cross-sectional part of the
study. Respondents can choose to receive a £5 voucher
on receipt of the questionnaire by providing postal con-
tact details.
Table 1 indicates the measures to be used, with which
respondents, and at what time points.
Sample size
The primary outcome is the Health Care Climate Ques-
tionnaire (HCCQ-10), identified by our user consultation
group as their preferred outcome measure. However,
data on the use of this scale with service users with se-
vere mental illness is limited and so we have used a stan-
dardised effect to calculate sample size and power. A
trial with 12 clusters per arm and a mean of 20 service
users per cluster (total sample size of 480) will provide
power greater than 80 % to detect a standardised effect
size of 0.4. This assumes an intra-cluster correlation co-
efficient of 0.05 and an 80 % follow-up rate, giving 384
participants with complete data in the analysis. Powerwill be increased by inclusion of baseline covariates (see
Statistical analysis below).
For the cross-sectional component, the primary out-
come remains the HCCQ-10. We aim to recruit at least
the same number of participants in each cluster; given
that the same clusters will be assessed as the cohort
component. As with the cohort component a sample
size of 384 in the cross-sectional component will ensure
power greater than 80 % in the corresponding analysis.
Any additional data gathered should increase power.
Recruitment
Trust managers have agreed that we can recruit CMHTs.
To recruit professionals we will use our applicants to
champion the study. Teams will be introduced to the
trial via a letter of support from the chief executive, and/
or via meetings with senior managers. Meetings will also
be held with area team managers (and if requested, staff )
across both sites to facilitate engagement with and un-
derstanding of the trial.
Recruitment and training will be undertaken in se-
quence, to maximise efficiency in delivery of training to
community teams, but also to ensure there is sufficient
time to permit the relevant baseline assessments to be
undertaken with service users (see below). CMHTs will
be randomly allocated to receive the EQUIP training or
control.
Recruitment of service users and carers - Cluster cohort
Service users will be excluded if their participation is
judged as inappropriate by the CMHTs: for example, if a
patient is not deemed to have capacity to provide fully
informed consent or is too unwell at the time of recruit-
ment. We will seek to document all exclusions and re-
port them as part of the trial CONSORT diagram.
Any carer (aged 18 years or older) of the service user
will be eligible for inclusion in the ‘cluster cohort’ study
if they agree to take part. Consent will be implied by re-
sponse via completion and return of the baseline ques-
tionnaires (and return of the consent to contact form if
they wish to be contacted at 6-month follow-up).
To recruit service users in the ‘cluster cohort’, the dir-
ect care team within the CMHTs (cluster) will produce a
list of all service users who meet eligibility criteria to
participate in the trial, including any reasons for exclu-
sions. This list will be referred to as their ‘caseload’.
These patient lists will be used by the NIHR Clinical Re-
search Network CSOs to send out an introductory letter,
participant information sheet and consent to contact
form to each patient, inviting them to take part in the
study. Service users will be required to ‘opt in’ by return-
ing the consent to contact form in a pre-paid envelope
to the research team. CSOs will contact non-responders
by telephone on one occasion to additionally allow
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team will then follow-up the consent to contact forms,
to answer any further questions, and when a participant
is recruited, the researcher will continue with a face-to-
face informed consent process. Following signed con-
sent, service users will be invited to complete all baseline
measures.
Service users will be asked at the informed consent
meeting to nominate a carer to be included in the study
and, if they choose to do so, will be provided with a
questionnaire pack (including introductory letter, infor-
mation sheet, questionnaire, pre-paid envelope and con-
sent to contact at 6-month follow-up form).
Service users who consent to take part in the trial will
be offered the opportunity to take part in the process
evaluation based on a purposive sampling framework to
ensure variation in gender, age and randomised group.
Potential participants will be provided with an invitation
letter, information sheet and consent to contact form
during the baseline meeting.
Recruitment of service users – Cluster cross-sectional
To recruit service users in the ‘cluster cross-sectional’
study, we will conduct a postal survey of all service users
under the care of each community mental health team 6
months after randomisation, excluding those already re-
cruited to the ‘cluster cohort’.
Sequence generation and allocation concealment
Once service users and carers have been sent a trial invi-
tation pack (following caseload review), the clusters will
be allocated randomly to either intervention or control.
To eliminate selection bias, allocation will be determined
through an external telephone randomisation service at
the Clinical Trials Unit of the Manchester Academic
Health Science Centre.
Clusters will be submitted to the randomisation ser-
vice in pairs. Each pair will be from the same site and
similarly matched in other characteristics where possible,
to reduce imbalance between intervention and control
arms. One member of the pair will be allocated to inter-
vention by random selection, the other allocated to
control.
Blinding
To reduce detection bias, we will seek to blind re-
searchers undertaking assessments of the quality of care
planning to the allocation. We will report the success or
otherwise of our attempts at blinding.
Data management
All data will be stored securely in line with local data
management arrangements. All questionnaires and other
paper records will be stored in secure storage facilities atthe University of Manchester and the University of
Nottingham. Personal identifiable paper records will be
stored separate from anonymised paper records. All
electronic records will be pseudo-anonymised using a
reference number for each participant and stored on a
password protected server at the University of
Manchester.
Statistical analysis
Analysis of outcomes will follow intention-to-treat prin-
ciples: outcome data will be sought and included in the
analysis for all service users irrespective of receipt of the
intervention or completion of care planning during the
time scale of the EQUIP trial.
Standard data checking procedures will be used as part
of the data cleaning procedure prior to locking the data-
base and linkage to group allocation. We will then
model the pattern of missing data in terms of baseline
characteristics of service users and treatment allocation
to check for differential non-response. Depending on the
patterns of missing data we may at this point choose to
use multiple-imputation. Multiple-imputation may also
be used in sensitivity analyses for non-ignorable missing
data assumptions [31].
For the cluster cohort study the intervention effects
for the primary outcome (HCCQ-10) and secondary out-
come measures will be estimated using a linear mixed
model with a random intercept for CMHTs. The base-
line value of the outcome will be used as a covariate to-
gether with other covariates pre-specified in the
statistical analysis plan. The same statistical modelling
procedure will be used for estimation of the intervention
effect in the cluster cross-sectional study using a re-
stricted set of covariates. Full detail of covariates for
each model will be confirmed in the statistical analysis
plan. We will then test for heterogeneity of the treat-
ment effect using the combined cohort and cross-
sectional data. If there is no evidence of heterogeneity,
we will estimate a pooled treatment effect.
A draft statistical analysis plan for primary and sec-
ondary outcomes, including sub-group analyses will be
presented to and agreed with the Programme Steering
Group prior to the commencement of the data analysis.
Economic analysis
A cost-effectiveness acceptability analysis will be con-
ducted from the perspectives of health and social care
providers and service users, the key stakeholders in
treatment decisions. The time horizon for the primary
economic analysis will be at scheduled follow-up (6
months). Data on service use and health status (EQ-
5D-5L) for the economic analysis will be collected for
all participants at baseline and follow-up and via the
cross-sectional survey. The economic analysis will
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costs or QALYs. Bootstrap techniques will be used to
estimate the cost-effectiveness acceptability curve, like-
lihood that the intervention could be cost-effective and
net benefit statistic.
The objective of the economic study will be to assess
the relative cost-effectiveness of the training intervention
to improve patient outcomes and/or reduce the costs of
health and social care.
Process evaluation
A process evaluation of the training programme delivered
as part of the trial is deemed appropriate because success-
ful implementation of the user/carer-led care planning
training implicates a range of factors including the integ-
rity of the intervention and the acceptability of the inter-
vention to both clinicians and service users [17].
The process evaluation is designed to explore by how
far the user/carer-led care planning has been taken up
and implemented in the daily work of the health profes-
sionals who attended the training and what the conse-
quences of this uptake have been. It will complement
and supplement the evidence provided by the main ran-
domised trial, as recommended by the Medical Research
Council (MRC) framework for evaluation of complex
intervention [32]. The design and execution of the
process evaluation will draw on Normalisation Process
Theory (NPT) [33] from the outset as well as other the-
ories of implementation science. NPT comprises four
components: coherence (sense making work), cognitive
participation (relational work), collective action (oper-
ational work), reflexive monitoring (appraisal work).
NPT has been developed from empirical studies of the
implementation of complex interventions in health care
contexts and in relation to mental health contexts in
particular. We will focus on: (a) implementation of user/
carer-involved care planning – the way this is developed
and translated into practices (of mental health profes-
sionals, users, carers and others); (b) embedding – the
manner in which care planning becomes, (or does not
become), routinely incorporated in everyday work of ser-
vice users and professionals; (c) integration – how care
planning is sustained as part of the everyday lives of in-
dividuals at work and at home; and d) networking –
how it generates access to new networks and resources.
Informed consent
The key ethical concerns for the programme include
confidentiality, participant anonymity and informed con-
sent to participate. The study includes both mental
health service users and carers as participants and, as
such, there are specific ethical issues to be considered.
Research governance principles and ethical committee
approvals bind all applicants and institutions. We willensure we adopt the highest standards of research con-
duct including involvement of service user representa-
tion in the management and delivery of the research.
The study will be conducted in compliance with the
study protocol, Good Clinical Practice (GCP) and both
University and NHS regulatory and monitoring require-
ments. The Work stream teams will meet every 3
months and the chief investigator (CI) will be respon-
sible for the overall leadership, management and outputs
of the programme. The principal investigator (PI) from
each site will maintain a log of the key milestones to be
achieved against the timetable. The programme man-
agers and Work stream leads will be responsible for the
day to day running and co-ordination of the studies and
will be accountable to the PI. All research associates will
be supervised by the Work stream leads.
All potential participants will be provided with an in-
formation sheet written to current NRES guidelines and
favourably reviewed by the relevant ethics committee,
prior to the study commencing. Service users and carers
have been involved in developing the participant infor-
mation sheets to ensure they are accessible. The infor-
mation sheet will be provided to potential participants at
the point of them expressing an interest in participating.
It will provide potential participants with information
about the study, including the potential benefits and
risks of taking part, confidentiality and the right to with-
draw. Researcher contact details will be provided so par-
ticipants can contact them with any queries prior to the
participant deciding whether or not to take part. Re-
searchers will further discuss risks and benefits immedi-
ately prior to the data collection taking place.
Participants in randomised trials usually provide writ-
ten informed consent for a range of research procedures,
including participation in the trial, randomisation and
data collection. However, conventional informed consent
procedures are not always appropriate in the context of
a cluster, randomised trial [34]. In the EQUIP trial, com-
munity mental health services are making the decision
to take part in the EQUIP trial and agree to randomised
allocation. This is described as a ‘cluster cluster’ design,
and is distinguished from an ‘individual cluster’ design
[35]. In the latter, randomisation is at the level of the
cluster, but specific services are delivered to individuals,
and service users can consent to receive or not receive
that intervention. The recent CADET trial was an ex-
ample of an individual cluster design [36]. In ‘cluster
cluster’ designs such as the EQUIP trial, service users
cannot opt out of a cluster in the same way, as the com-
munity teams will have been trained in the new
methods. The recent WISE study was an example of this
design [37].
In the EQUIP trial, seeking formal consent for participa-
tion and randomisation may, therefore, be inappropriate,
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users. The following consent procedures will be adopted.
If the service, and the CMHTs consent to take part in
the trial, then individual service users will not be asked
for specific consent to be randomised as part of the
EQUIP trial. Service users cannot, therefore, ‘opt out’ of
their cluster allocation. The Clinical Research Network
CSOs (or Trust staff ) will be responsible for accessing
patient details and determining who is eligible to take
part in the study and be contacted. They will be respon-
sible for sending out information about the study to the
identified service users, along with an invitation to par-
ticipate. The research team will not have access to ser-
vice user details until they have returned the consent to
contact form.
Service users in the ‘cluster cohort’ will undertake a
detailed face-to-face assessment at 2 points in time
(baseline and 6 months). For these, a formal written
consent procedure will be adopted. It will be explained
to service users that their CMHT is involved in a study
to test the effectiveness of a new training package on
service user/carer involvement in care planning com-
pared to the usual care planning experience. Participants
will be told that we will do this by delivering the training
to some mental health teams and not to other teams to
see if receiving the training has an impact on the extent
of service user/carer involvement in care planning.
Carers in the ‘cluster cohort’ will undertake a postal
survey at baseline and at 6 months. Carers will be asked
to participate via nomination by a service user. Response
to the questionnaires will be treated as consent. Carers
will also be asked to complete a consent to contact form
to allow invitation to complete the follow-up question-
naire at 6 months, which is returnable to the research
team in the prepaid envelope provided.
Service users in the ‘cross-sectional sample’ will under-
take a short postal survey at 6 months only. For these,
we will treat this part of the study as a survey. Service
users will receive a postal invitation to the survey, seek-
ing their views on the quality of the care planning
process that they have received. Response to the survey
will be treated as consent, as is usual in survey work.
Participants may change their mind and withdraw from
the study at any point and this will not affect the care
they receive.
Ethics
The study received a favourable ethical opinion from the
National Research Ethics Service (NRES) on 8 August
2014 (NRES Committee North West Lancaster, REC
Reference 14/NW/0297; IRAS Project ID 125899). It will
be conducted in accordance with the UK Department of
Health Research Governance Framework in Health and
Social Care (2005) and adhere to the ethical principles ofthe Helsinki Declaration (2013). All research staff in-
volved in the conduct of the trial will meet the standards
laid out in the ICH Tripartite Guideline for Good Clin-
ical Practice (1996).
All data will be anonymised and secured off site fol-
lowing data input for a period of at least 5 years in ac-
cordance with the Data Protection Act (1995).
The design of this trial will not disadvantage service
users in either the care planning training groups or con-
trol groups. No treatment is being withheld from service
users in the control group.Ancillary studies
Data from an embedded sub-study will contribute to a
programme of research (www.population-health.man-
chester.ac.uk/mrcstart/) funded by the MRC to expand
the relatively small evidence base on an important issue
concerning the recruitment of participants to trials [38].
It is recognised that patient and public involvement
(PPI) is an important part of designing studies that are
sensitive to the needs and preferences of patients, and
the EQUIP study has invested significant time and re-
sources into ensuring that PPI on the project receives
sufficient focus. The embedded sub-study (‘START in
EQUIP’, funded through an NIHR Doctoral Research
Fellowship – award number DRF-2012-05-128) aims to
evaluate whether telling eligible patients directly about
the PPI in EQUIP increases patient recruitment into the
study.
Service users will be randomised to receive a flyer de-
tailing the extensive PPI in EQUIP alongside the stand-
ard participant information sheet, or the standard
participant information sheet alone. This will be imple-
mented by using cluster randomisation, in a crossed-
factorial design with the main EQUIP allocation. We will
test whether receiving the flyer is associated with higher
levels of recruitment into EQUIP.Discussion
Involving service users in planning their care is at the
centre of policy initiatives in the United Kingdom to im-
prove quality of mental health care. Users value care
planning and involvement in care, but achieving this in
practice is far from straightforward.
Our aim is to evaluate the effectiveness and cost-
effectiveness of training for mental health professionals
in improving user involvement with the care planning
processes. We have designed and delivered a pragmatic
trial which will test this training and its impact in the
context of routine care delivery. We have adopted very
simple inclusion criteria to include as broad a range of
patients as possible and enhance the pragmatic nature of
the trial.
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care raises significant logistical challenges. Recruiting ad-
equate numbers of patients in the limited recruitment
window prior to training is proving challenging, and
busy services can struggle to provide time for staff to at-
tend the relevant training sessions when faced with sig-
nificant clinical pressures.
The planned process evaluation will allow us to ex-
plore the impact of these pressures on delivery and im-
plementation of the training. If successful in improving
outcomes, we will be active in disseminating and imple-
menting the results of the trial.
Trial status
CMHTs in the first 18 clusters have been randomised
and training of staff in the experimental arm of these
clusters completed. Randomisation and training of the
remaining clusters will continue until December 2015.
Recruitment and data collection of primary and second-
ary outcomes with service users and carers began in July
2014 and will continue until June 2016.
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